Pre-Exposure Prophylaxis (PrEP) in the Prevention of HIV: Strategies, Target Populations and Upcoming Treatments

References

• Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States – 2017 update; Available from: 2018 https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf. Accessed 129, 2019.
   Google Scholar
• US Food and Drug Administration. FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic; 2019 Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-second-drug-prevent-hiv-infection-part-ongoing-efforts-end-hiv-epidemic. Accessed 1210, 2019.
   Google Scholar
• European AIDS Clinical Society. Guidelines – version 10.0; 2019 Available from: https://www.eacsociety.org/files/2019_guidelines-10.0_final.pdf. Accessed 1212, 2019.
   Google Scholar
• Centers for Disease Control and Prevention. PrEP. 2019 https://www.cdc.gov/hiv/basics/prep.html. Accessed 1210, 2019.
   Google Scholar
• AIDSvu. Mapping PrEP: first ever data on PrEP users across the US. Emory university rollins school of public health; 2020 Available from: https://aidsvu.org/prep/. Accessed 112, 2020.
   Google Scholar
• World Health Organization. Pre-exposure prophylaxis; 2020 Available from: https://www.who.int/hiv/topics/prep/en/. Accessed 211, 2020.
   Google Scholar
• Pyra M, Haberer J, Hasen N, Reed J, Mugo N, Baeten J. Global implementation of PrEP for HIV prevention: setting expectations for impact. J Int AIDS Soc. 2019;22(8):e25370. doi:10.1002/jia2.2537031456348
   PubMed Web of Science ®Google Scholar
• UNAIDS. Access to PrEP being held back; 2019 Available from: https://www.unaids.org/sites/default/files/media/images/access-to-PrEP-being-held-back.png. Accessed 211, 2020.
   Google Scholar
• Pinto R, Berringer K, Melendez R, Mmeje O. Improving PrEP implementation through multilevel interventions: a synthesis of the literature. AIDS Behav. 2018;22(11):3681–3691. doi:10.1007/s10461-018-2184-429872999
   PubMed Web of Science ®Google Scholar
• Brooks R, Allen Jr V, Regan R, Mutchler M, Cervantes-Tadeo R, Lee S. HIV/AIDS conspiracy beliefs and intention to adopt HIV pre-exposure prophylaxis among black men who have sex with men in Los Angeles. Int J STD AIDS. 2018;29(4):375–381. doi:10.1177/095646241772769128853676
   PubMed Web of Science ®Google Scholar
• Page K, Martinez O, Nieves-Lugo K, et al. Promoting pre-exposure prophylaxis to prevent HIV infections among sexual and gender minority Hispanics/Latinxs. AIDS Educ Prev. 2017;29(5):389–400. doi:10.1521/aeap.2017.29.5.38929068715
   PubMed Web of Science ®Google Scholar
• Martinez O, Wu E, Levine E, et al. Integration of social, cultural, and biomedical strategies into an existing couple-based behavioral HIV/STI prevention intervention: voices of Latino male couples. PLoS One. 2016;11(3):e0152361. doi:10.1371/journal.pone.015236127028873
   PubMed Web of Science ®Google Scholar
• Palazzolo S, Yamanis T, De Jesus M, Maguire-Marshall M, Barker S. Documentation status as a contextual determinant of HIV risk among young transgender Latinas. LGBT Health. 2016;3(2):132–138. doi:10.1089/lgbt.2015.013326669583
   PubMed Web of Science ®Google Scholar
• Sullivan P, Mena L, Elopre L, Siegler A. Implementation strategies to increase PrEP uptake in the South. Curr HIV/AIDS Rep. 2019;16(4):259–269. doi:10.1007/s11904-019-00447-431177363
   PubMed Web of Science ®Google Scholar
• Tung E, Thomas A, Eichner A, Shalit P Feasibility of a pharmacist-run HIV PrEP clinic in a community pharmacy setting. In: Conference on Retroviruses and Opportunistic Infections (CROI) Accessed 710, 2020; Seattle, WA 2017 http://www.croiconference.org/sessions/feasibility-pharmacist-run-hiv-prep-clinic-community-pharmacy-setting.
   Google Scholar
• Tung E, Thomas A, Eichner A, Shalit P. Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care. Sex Health. 2018;15(6):556–561. doi:10.1071/SH1808430401342
   PubMedGoogle Scholar
• Myers J, Farhat D, Guzman A, Arya V. Pharmacists in HIV prevention: an untapped potential. Am J Public Health. 2019;109(6):859–861. doi:10.2105/AJPH.2019.30505731067105
   PubMedGoogle Scholar
• Hamm N. California bill increases pharmacist powers: new bill allows pharmacists to initiate HIV medication. Drug Topics. 2019;163(11):36.
   Google Scholar
• Khosropour C, Backus K, Means A, et al. A pharmacist-led, same-day, HIV pre-exposure prophylaxis initiation program to increase PrEP uptake and decrease time to PrEP initiation. AIDS Patient Care STDS. 2020;34(1):1–6. doi:10.1089/apc.2019.023531944854
   PubMed Web of Science ®Google Scholar
• Smith B, Hester A, Cantos V, James T, Lora M. A pharmacist-led PrEP program at the epicenter of the HIV epidemic in Atlanta; our experience. Open Forum Infectious Diseases 2019; 6(suppl 2):S461. doi:10.1093/ofid/ofz360.1143.
   Google Scholar
• Hoth A, Shafer C, Dillon D, Mayer R, Walton G, Ohl M. Iowa TelePrEP: a public-health-partnered telehealth model for HIV pre-exposure prophylaxis (PrEP) delivery in a rural state. Sex Transm Dis. 2019;46(8):507–512. doi:10.1097/OLQ.000000000000101731295217
   PubMed Web of Science ®Google Scholar
• Keenan R, Lewis J, Sanchez D, Anderson B, Mercier R. The Next Step in PrEP: Evaluating Outcomes of a Pharmacist-Run HIV Pre-Exposure Prophylaxis (Prep) Clinic. ID Week; 2018.
   Google Scholar
• Siegler A, Bratcher A, Weiss K. Geographic access to preexposure prophylaxis clinics among men who have sex with men in the United States. Am J Public Health. 2019;109(9):1216–1223. doi:10.2105/AJPH.2019.30517231318587
   PubMed Web of Science ®Google Scholar
• Refugio O, Kimble M, Silva C, Lykens J, Bannister C, Klausner J. Brief report: prEPTECH: a telehealth-based initiation program for HIV pre-exposure prophylaxis in young men of color who have sex with men. A pilot study of feasibility. J Acquir Immune Defic Syndr. 2019;80(1):40–45. doi:10.1097/QAI.000000000000187330272632
   PubMed Web of Science ®Google Scholar
• Stekler J, McMahan V, Ballinger L, et al. HIV pre-exposure prophylaxis prescribing through telehealth. J Acquir Immune Defic Syndr. 2018;77(5):e40–e42. doi:10.1097/QAI.000000000000162129280768
   PubMedGoogle Scholar
• Liu A, Vittinghoff E, von Felten P, et al. Randomized controlled trial of a mobile health intervention to promote retention and adherence to preexposure prophylaxis among young people at risk for human immunodeficiency virus: the EPIC study. Clin Infect Dis. 2019;68(12):2010–2017. doi:10.1093/cid/ciy81030239620
   PubMed Web of Science ®Google Scholar
• Sullivan P, Driggers R, Stekler J, et al. Usability and acceptability of a mobile comprehensive HIV prevention app for men who have sex with men: a pilot study. JMIR Mhealth Uhealth. 2017;5(3):e26. doi:10.2196/mhealth.719928279949
   PubMed Web of Science ®Google Scholar
• Biello K, Oldenburg C, Mitty J, et al. The “safe sex” conundrum: anticipated stigma from sexual partners as a barrier to PrEP use among substance using MSM engaging in transactional sex. AIDS Behav. 2017;21(1):300–306. doi:10.1007/s10461-016-1466-y27351194
   PubMed Web of Science ®Google Scholar
• Golub S, Gamarel K, Surace A. Demographic differences in PrEP-related stereotypes: implications from implementation. AIDS Behav. 2017;21(5):1229–1235. doi:10.1007/s10461-015-1129-426143247
   PubMed Web of Science ®Google Scholar
• Dubov A, Galbo P, Altice F, Fraenkel L. Stigma and shame experiences by MSM who take PrEP for HIV prevention: a qualitative study. Am J Mens Health. 2018;12(6):1843–1854. doi:10.1177/155798831879743730160195
   PubMed Web of Science ®Google Scholar
• Golub S. PrEP stigma: implicit and explicit drivers of disparity. Curr HIV/AIDS Rep. 2018;15(2):190–197. doi:10.1007/s11904-018-0385-029460223
   PubMed Web of Science ®Google Scholar
• Lynn V, Watson C, Giwa-Onaiwu M, Ray V, Gallagner B, Wojciechowicz V. HIV #languagematters: addressing stigma by using preferred language. Available from: https://hiveonline.org/wp-content/uploads/2016/01/Anti-StigmaSign-Onletter1.pdf. Accessed 710, 2020.
   Google Scholar
• Gallagher K, Updegraff J. Health message framing effects on attitudes, intentions, and behavior: a meta-analytic review. Ann Behav Med. 2012;43(1):101–116. doi:10.1007/s12160-011-9308-721993844
   PubMed Web of Science ®Google Scholar
• Castro D, Delabre R, Molina J. Give PrEP a chance: moving on from the “risk compensation” concept. J Int AIDS Soc. 2019;22(6):e25351. doi:10.1002/jia2.2535131468693
   PubMedGoogle Scholar
• Volk J, Marcus J, Phengrasamy T, et al. No new HIV infections with increasing use of HIV preexposure prophylaxis in a clinical practice setting. Clin Infect Dis. 2015;61(10):1601–1603. doi:10.1093/cid/civ77826334052
   PubMed Web of Science ®Google Scholar
• Jenness S, Goodreau S, Rosenberg E, et al. Impact of the centers for disease control’s HIV preexposure prophylaxis guidelines for men who have sex with men in the United States. J Infect Dis. 2016;214(12):1800–1807. doi:10.1093/infdis/jiw22327418048
   PubMedGoogle Scholar
• Anderson P, Glidden D, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012;4(151):151ra125. doi:10.1126/scitranslmed.3004006
   PubMed Web of Science ®Google Scholar
• Norris L A state-by-state guide to medicaid expansion, eligibility, enrollment and benefits; 2020 Available from: https://www.healthinsurance.org/medicaid/. Accessed 219, 2020.
   Google Scholar
• Private PrEP medication assistance program for uninsured patients. https://www.nastad.org/prepcost-resources/prep-assistance-programs#:~:text=WHAT IT COVERS%3A The program,individuals%2C regardless of immigration status.Accessed June 10, 2020. 
   Google Scholar
• PrEP patient assistance program (PrEP-AP). New York State; 2015 Available from: https://www.health.ny.gov/diseases/aids/general/prep/prep-ap_provider.htm. Accessed 219, 2020.
   Google Scholar
• Sullivan P, Giler R, Mouhanna F, et al. Trends in the use of oral emtricitabine/tenofovir disoproxil fumarate for pre-exposure prophylaxis against HIV infections, United States, 2012–2017. Ann Epidemiol. 2018;28(12):833–840. doi:10.1016/j.physbeh.2017.03.04030037634
   PubMed Web of Science ®Google Scholar
• Kanny D, Jeffries W, Chapin-Bardales J, et al. Racial/ethnic disparities in HIV preexposure prophylaxis among men who have sex with men – 23 urban areas, 2017; 2019 Morbidity and Mortality Weekly Report. Available from: https://www.cdc.gov/mmwr/volumes/68/wr/mm6837a2.htm#T1_down. Accessed 12, 2020.
   Google Scholar
• Rao S, Seth P, Walker T, et al. HIV testing and outcomes among Hispanics/Latinos – United States, Puerto Rico, and US Virgin Islands, 2014. Morb Mortal Wkly Rep. 2016;65(40):1099–1103. doi:10.15585/mmwr.mm6540a2
   PubMed Web of Science ®Google Scholar
• Eaton LA, Driffin DD, Bauermeister J, Smith H, Conway-Washington C. Minimal awareness and stalled uptake of Pre-Exposure Prophylaxis (PrEP) among at risk, HIV-negative, black men who have sex with men. AIDS Patient Care STDS. 2015;29(8):423–429. doi:10.1089/apc.2014.030326083143
   PubMed Web of Science ®Google Scholar
• Menza TW, Hughes JP, Celum CL, Golden MR. Prediction of HIV acquisition among men who have sex with men. Sex Transm Dis. 2009;36(9):547–555. doi:10.1097/OLQ.0b013e3181a9cc4119707108
   PubMed Web of Science ®Google Scholar
• Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60(4):421–427. doi:10.1097/QAI.0b013e318256b2f622487585
   PubMed Web of Science ®Google Scholar
• Pinkerton SD, Abramson PR. Effectiveness of condoms in preventing HIV transmission. Soc Sci Med. 1997;44(9):1303–1312. doi:10.1016/S0277-9536(96)00258-49141163
   PubMed Web of Science ®Google Scholar
• Do M, Meekers D. Multiple sex partners and perceived risk of HIV infection in Zambia: attitudinal determinants and gender differences. AIDS Care. 2009;21(10):1211–1221. doi:10.1080/0954012090273004720024696
   PubMed Web of Science ®Google Scholar
• Dean H, Steele C, Satcher A. HIV/AIDS among minority races and ethnicities in the United States, 1999–2003. J Natl Med Assoc. 2005;97(7 suppl):5S–12S.
   PubMed Web of Science ®Google Scholar
• Caponi M, Burgess C, Leatherwood A, Molano LF. Demographic characteristics associated with the use of HIV pre-exposure prophylaxis (PrEP) in an urban, community health center. Prev Med Rep. 2019;15:100889. doi:10.1016/j.pmedr.2019.10088931194089
   PubMedGoogle Scholar
• Lalota M, Beck D, Metsch L, et al. HIV seropositivity and correlates of infection among heterosexually active adults in high-risk areas in South Florida. AIDS Behav. 2011;15(6):1259–1263. doi:10.1007/s10461-010-9856-z21153433
   PubMedGoogle Scholar
• Jenness S, Neaigus A, Murrill C, Wendel T, Forgione L, Hagan H. Estimated HIV incidence among high-risk heterosexuals in New York city, 2007. J Acquir Immune Defic Syndr. 2011;56(2):193–197. doi:10.1097/QAI.0b013e318202a9c421233639
   PubMedGoogle Scholar
• The National Institute of Allergy and Infectious Diseases. Evaluating the safety and efficacy of the long-acting injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women. ClinicalTrials.gov identifier: NCT03164564. Available from: https://clinicaltrials.gov/ct2/show/NCT03164564#contacts. Accessed 27, 2020.
   Google Scholar
• Safety and efficacy study of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), for pre-exposure prophylaxis in HIV-uninfected cisgender men and transgender women who have sex with men. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02720094. Accessed 23, 2020.
   Google Scholar
• Gilead Sciences. A phase 3, randomized, double-blind study to evaluate the safety and efficacy of emtricitabine and tenofovir alafenamide (F/TAF) fixed-dose combination once daily for pre-exposure prophylaxis in men and transgender women who have sex with men and are at R. Clinical trials.gov identifier NCT02842086. Available from: https://clinicaltrials.gov/ct2/show/NCT02842086. Accessed 314, 2020.
   Google Scholar
• Nel A, Van Niekerk N, Kapiga S, et al. Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375(22):2133–2143. doi:10.1056/NEJMoa160204627959766
   PubMed Web of Science ®Google Scholar
• Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375(22):2121–2132. doi:10.1056/NEJMoa150611026900902
   PubMed Web of Science ®Google Scholar
• Baeten J, Palanee-Phillips T, Mgodi N, et al. High adherence and sustained impact on HIV-1 incidence: final results of an open-label extension trial of the dapivirine vaginal ring. In: 10th IAS Conference on HIV Science (IAS 2019); Accessed 710, 2020; W Sussex, England https://www.nih.gov/news-events/news-releases/most-women-use-vaginal-ring-hiv-prevention-open-label-study.
   Google Scholar
• Levin J HIV incidence and adherence in DREAM – an open-label trial of dapivirine vaginal ring – 2016/2018. In: Conference on Retroviruses and Opportunistic Infections (CROI).
   Google Scholar
• Nel A. Safety, adherence and HIV-1 seroconversion in DREAM – an open-label dapivirine vaginal ring trial. Slides presented at: SA AIDS Conference; June 11-14, 2019; Durban, South Africa. https://www.saaids.co.za/.cm4all/uproc.php/0/Hall%201/Hall%201/Dr%20Annalene%20Nel.pdf?cdp=a&_=16bd6bf1740. Accessed February 10, 2020
   Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID). Evaluating the safety of and adherence to a vaginal matrix ring containing dapivirine and oral emtricitabine/tenofovir disoproxil fumarate in an adolescent and young adult female population. Available from: https://aidsinfo.nih.gov/clinical-trials/details/NCT03593655. Accessed 27, 2020.
   Google Scholar
• National Institute of Allergy and Infectious Diseases. Evaluating the safety and efficacy of the VRC01 antibody in reducing acquisition of HIV-1 infection among men and transgender persons who have sex with men. Available from: https://clinicaltrials.gov/ct2/show/NCT02716675. Accessed 27, 2020.
   Google Scholar
• Crowell TA, Colby DJ, Pinyakorn S, et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV. 2019;6(5):e297–e306. doi:10.1016/S2352-3018(19)30053-031000477
   PubMed Web of Science ®Google Scholar
• Johnson LM, Krovi SA, Li L, et al. Characterization of a reservoir-style implant for sustained release of tenofovir alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP). Pharmaceutics. 2019;11(7):315. doi:10.3390/pharmaceutics11070315
   PubMed Web of Science ®Google Scholar
• Gatto G, Girouard N, Brand RM et al. Pharmacokinetics of tenofovir alafenamide by subcutaneous implant for HIV PrEP. In: Conference on Retroviruses and Opportunistic Infections (CROI); Accessed 710, 2020; Boston, MA http://www.croiconference.org/sessions/pharmacokinetics-tenofovir-alafenamide-subcutaneous-implant-hiv-prep.
   Google Scholar
• Immediate or deferred Pre-exposure Prophylaxis for HIV prevention: safe options for pregnant and lactating women (PrEP). ClinicalTrials.gov identifier: NCT03227731. Available from: https://clinicaltrials.gov/ct2/show/NCT03227731. Accessed 23, 2020.
   Google Scholar
• Expanded PrEP implementation in communities in NSW (EPIC-NSW). ClinicalTrials.gov identifier: NCT02870790. https://clinicaltrials.gov/ct2/show/NCT02870790. Accessed 23, 2020.
   Google Scholar